Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal …

M Kamboj, JC Laracy, S Usiak, NE Babady, J Yan… - 2023 - cabidigitallibrary.org
Skip the header click to show the menu Menu Cart Login Login/Register Institutional Access
Access Options Enter words / phrases / DOI / ISBN / keywords / authors / etc Search Advanced …
被引用次数：3 相关文章

[引用][C] Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of …

M Kamboj, JC Laracy, S Usiak, NE Babady… - Journal of …, 2023 - journalofinfection.com
We read with great interest the recent article by Touret et al., in which they described nearly
undetectable Omicron BQ. 1.1 neutralization by patients' sera following receipt of …

Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal …

M Kamboj, JC Laracy, S Usiak… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after
tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant …

[引用][C] Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of …

M Kamboj, JC Laracy, S Usiak, NE Babady… - The Journal of …, 2023 - europepmc.org
Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after
tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant …